A. Shoemaker

发表

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

S. Korsmeyer, A. Letai, P. Hajduk, 2005, Nature.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

C. Tse, S. Fesik, Eric F. Johnson, 2008, Cancer research.

PARP inhibitors attenuate chemotherapy‐induced painful neuropathy

K. Browman, X. Liu, V. Giranda, 2012, Journal of the peripheral nervous system : JPNS.

Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer

T. Ward, C. Dive, D. Micha, 2008, Clinical Cancer Research.

Retinoic acid nuclear receptors and tumor promotion: decreased expression of retinoic acid nuclear receptors by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.

A. Shoemaker, A. Verma, R. Kumar, 1994, Carcinogenesis.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Mlh1 deficiency enhances several phenotypes of ApcMin/+ mice

S. Dudley, K. Haigis, A. Shoemaker, 2000, Oncogene.

Hypoxia-Inducible Factor-1 Inhibition in Combination with Temozolomide Treatment Exhibits Robust Antitumor Efficacy In vivo

S. Fesik, D. Albert, A. Shoemaker, 2006, Clinical Cancer Research.

Preclinical Development The Bcl-2 / Bcl-XL / Bcl-w Inhibitor , Navitoclax , Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

C. Tse, H. Maecker, S. Rosenberg, 2011 .

Investigation of biaryl heterocycles as inhibitors of Wee1 kinase.

K. Bromberg, Eric F. Johnson, N. Soni, 2019, Bioorganic & medicinal chemistry letters.

246 Novel ATP-competitive Akt inhibitors slow the progression of tumors in vivo

X. Liu, V. Giranda, Yan Luo, 2004 .

Af-Ethyl-W-nitrosourea Treatment of Multiple Intestinal Neoplasia (Afin) Mice: Age-related Effects on the Formation of Intestinal Adenomas, Cystic Crypts, and Epidermoid Cysts1

William, A. Moser, A. Shoemaker, 2006 .

Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet.

A. Shoemaker, A. Verma, M. Denning, 1992, The Journal of nutrition.

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy

Tzu-Hsuan Huang, A. Shoemaker, U. Ladror, 2019, PloS one.

Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

J. Fisher, X. Liu, V. Giranda, 2005, Neoplasia.

The adenomatous polyposis coli gene of the mouse in development and neoplasia.

A. Moser, A. Shoemaker, W. Dove, 1994, Cold Spring Harbor symposia on quantitative biology.

Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-A

Eric F. Johnson, X. Liu, V. Giranda, 2011, The Journal of Biological Chemistry.

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Eric F. Johnson, X. Liu, V. Giranda, 2009, Molecular Cancer Research.

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

K. Swinger, Eric F. Johnson, N. Soni, 2013, ACS medicinal chemistry letters.

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Saul H Rosenberg, Xiaohong Song, Milan Bruncko, 2008, Journal of medicinal chemistry.

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity.

Mikkel A. Algire, K. Comess, Chaohong Sun, 2017, Nature chemical biology.

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

P. Ellis, Eric F. Johnson, X. Liu, 2012, Bioorganic & medicinal chemistry.

Aminopyrimidinone cdc7 kinase inhibitors.

Eric F. Johnson, N. Soni, J. Miyashiro, 2012, Bioorganic & medicinal chemistry letters.

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.

M. Staver, S. Fesik, D. Semizarov, 2005, Cancer research.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.

Eric F. Johnson, X. Liu, V. Giranda, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Shi, V. Stoll, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Principles of Chemotherapy and Pharmacology

A. Shoemaker, C. Donawho, J. Palma, 2007 .

ApcMin: a mouse model for intestinal and mammary tumorigenesis.

A. Moser, A. Shoemaker, W. Dove, 1995, European journal of cancer.

Somatic mutational mechanisms involved in intestinal tumor formation in Min mice.

L. Marton, A. Moser, A. Shoemaker, 1997, Cancer research.

Studies of neoplasia in the Min mouse.

A. Moser, A. Shoemaker, W. Dove, 1997, Biochimica et biophysica acta.

Homozygosity for the Minallele of Apc results in disruption of mouse development prior to gastrulation

A. Moser, A. Shoemaker, L. Clipson, 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

Manipulation of the mouse germline in the study of Min-induced neoplasia.

A. Shoemaker, W. Dove, K. Gould, 1996, Seminars in cancer biology.

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

C. Tse, M. Michaelides, W. N. Pappano, 2015, PloS one.

A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice.

C. Midgley, A. Moser, A. Shoemaker, 1998, Proceedings of the National Academy of Sciences of the United States of America.

The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions.

M. Newton, A. Merritt, A. Shoemaker, 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

Saul H Rosenberg, Chaohong Sun, R. Meadows, 2004, Journal of medicinal chemistry.

Inhibitor , Navitoclax , Enhances the Activity of Chemotherapeutic Agents in vitro and in vivo

C. Tse, H. Maecker, S. Rosenberg, 2011 .

Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function.

Richard B Halberg, Peter D Hoff, Kevin M Haigis, 2004, Proceedings of the National Academy of Sciences of the United States of America.

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

C. Tse, H. Maecker, S. Rosenberg, 2011, Molecular Cancer Therapeutics.

CPD Damage Recognition by Transcribing RNA Polymerase II

S. Korsmeyer, D. Vaux, S. Lowe, 2007 .

The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.

Ryan A McClure, K. Longenecker, Chaohong Sun, 2022, ACS chemical biology.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.

A. Vasudevan, Chaohong Sun, C. Jakob, 2018, Journal of medicinal chemistry.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

A. Vasudevan, Eric F. Johnson, V. Giranda, 2012, Bioorganic & medicinal chemistry letters.

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts.

A. Moser, A. Shoemaker, W. Dove, 1995, Cancer research.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.

K. Bromberg, Eric F. Johnson, N. Soni, 2015, ACS medicinal chemistry letters.

Emergent issues in the genetics of intestinal neoplasia.

A. Moser, A. Shoemaker, W. Dove, 1995, Cancer surveys.

Mlh 1 de ® ciency enhances several phenotypes of Apc Min / + mice

S. Dudley, K. Haigis, A. Shoemaker, 2000 .

Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.

Yan Shi, X. Liu, V. Giranda, 2004, Anticancer research.